Bionure exceeded the one million euros initially expected in its crowdfunding campaign and plans to allocate these resources to the development of BN201, an innovative drug against multiple sclerosis that has the potential to stop the advance of the disease (El Periódico). Multiple sclerosis, which is currently incurable, affects 2.5 million people worldwide, 600,000 in Europe and 47,000 in Spain.

Bionure has granted Spiral Therapeutics a license to develop BN201 and BN119 (for the treatment of the inner ear disorders). Spiral Therapeutics, founded by Hugo Peris in San Francisco (Silicon Valley), will soon start a feasibility assessment to determine the potential of these two candidates. You can extend this information in this article.